{"id":152435,"date":"2017-10-16T15:35:02","date_gmt":"2017-10-16T15:35:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=152435"},"modified":"2017-10-16T15:35:02","modified_gmt":"2017-10-16T15:35:02","slug":"gingivostomatitis-market-by-treatment-nonsteroidal-antiinflammatory-drugs-antiviral-antibacterial-and-forecasts-to-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gingivostomatitis-market-by-treatment-nonsteroidal-antiinflammatory-drugs-antiviral-antibacterial-and-forecasts-to-2023_152435.html","title":{"rendered":"Gingivostomatitis Market by Treatment – Non-Steroidal Anti-Inflammatory Drugs, Antiviral, Antibacterial and Forecasts To 2023"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Market Research Futurern”<\/div>\n<\/div>\n<\/div>\n
Global Gingivostomatitis Market report titled \u201cGlobal Gingivostomatitis Market Research Report- Forecast To 2023\u201d Based on treatment, the market has been segmented as non-steroidal anti-inflammatory drugs, antiviral and antibacterial, debridement of the mouth and others.<\/div>\n

The Global Gingivostomatitis Market is expected to reach USD 15.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.6 % during the forecast period 2017-2023.<\/span><\/span><\/p>\n

The Worldwide Gingivostomatitis Market report analyzes the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. The Global <\/span><\/span>Gingivostomatitis Market<\/span><\/span><\/strong><\/a> report provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. Gingiva means gums and stomata refer to mouth. Gingivostomatitis is a combination of gingivitis and stomatitis, which is the inflammation of the oral mucosa and gingiva. Gingivostomatitis is most commonly caused by herpes simplex virus type 1 (HSV-1), coxsackievirus, bacteria such as Streptococcus, Actinomyces etc. Poor oral hygiene is an important risk factor for Gingivostomatitis. <\/span><\/span><\/p>\n

Get Sample Copy @ <\/span><\/span><\/strong>https:\/\/www.marketresearchfuture.com\/sample_request\/4402<\/span><\/span><\/a> .<\/span><\/span><\/p>\n

Symptoms of gingivostomatitis may include tender sores on the gums or cheeks, bad breath, fever, swollen gums and lymph nodes, bleeding, difficulty in eating etc. Gingivostomatitis is a common infection of the mouth and gums and frequently occurs in children. If left untreated complications such as severe mouth ulcers can occur. Gingivostomatitis is caused in 90% of cases by herpes simplex virus type 1. Acyclovir and penciclovir are the drugs of choice for the treatment of herpes simplex virus type 1, but microbial resistance has been on a rise which has led to high degree of clinical failures. Thus there is an unmet need for a new drug with selectivity and lethal action against of herpes simplex virus. Development of any new drug for the treatment of herpes simplex virus will be met with great market enthusiasm with a minimum of marketing costs and efforts. <\/span><\/span><\/p>\n

The Americas accounted for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products in the US drives the Gingivostomatitis market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger market for oral hygiene products is adding fuel to the market growth. The large expenditure by the US on healthcare accounting to 16% of GDP also cruises the sale of Gingivostomatitis treatment.<\/span><\/span><\/p>\n

Europe is the second largest market in the world due to high income and healthcare penetration. Europe is led by countries such as Germany and France. UK is expected to be the fastest growing market. The large influence of media and the rise in awareness of oral hygiene coupled with the high per capita income of the population drives the European market for Gingivostomatitis.<\/span><\/span><\/p>\n

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asia countries such as Vietnam, Thailand and Malaysia will also contribute highly to the market.<\/span><\/span><\/p>\n

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However it has to be noted that Africa has the highest unmet needs in the world and cost effective products will be the key to dominate the African market. First comer advantage and established dominance in African market are advantages that will be difficult to overcome by any new player due to the smaller market size and market value of the African market for Gingivostomatitis.<\/span><\/span><\/p>\n

Some of the key players in this market are Pfizer Inc., Taj Pharmaceutical limited., Ciron pharma, Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc. Novartis, F. Hoffman La Roche AG, Eli Lily and Company, AstraZeneca Plc., and others.<\/span><\/span><\/p>\n

Get Discount @<\/span><\/span><\/strong> https:\/\/www.marketresearchfuture.com\/check-discount\/4402<\/span><\/span><\/a> .<\/span><\/span><\/p>\n

Major TOC of Gingivostomatitis Market:<\/span><\/span><\/strong><\/p>\n

Research Methodology<\/span><\/span><\/p>\n

Market Dynamics<\/span><\/span><\/p>\n

Global Gingivostomatitis Market, Applications<\/span><\/span><\/p>\n

Global Gingivostomatitis Market, By Types<\/span><\/span><\/p>\n

Global Gingivostomatitis Market, By Competitive Landscape<\/span><\/span><\/p>\n

Global Gingivostomatitis Market, By Region<\/span><\/span><\/p>\n

Competitive Landscape<\/span><\/span><\/p>\n

Company Profiles<\/span><\/span><\/p>\n

….Continued<\/span><\/span><\/strong><\/p>\n

About US:<\/span><\/span><\/strong><\/p>\n

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.<\/span><\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Market Research Future
Contact Person:<\/strong> Akash Anand
Email:<\/strong> akash.anand@marketresearchfuture.com
Phone:<\/strong> +1 646 845 9312
Address:<\/strong>Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> https:\/\/www.marketresearchfuture.com\/reports\/gingivostomatitis-market-4402<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Market Research Futurern” Global Gingivostomatitis Market report titled \u201cGlobal Gingivostomatitis Market Research Report- Forecast To 2023\u201d Based on treatment, the market has been segmented as non-steroidal anti-inflammatory drugs, antiviral and antibacterial, debridement of the mouth and others. The Global Gingivostomatitis … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-152435","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/152435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=152435"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/152435\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=152435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=152435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=152435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}